TY  - JOUR
AU  - González-Martín, Antonio
AU  - Desauw, Christophe
AU  - Heitz, Florian
AU  - Cropet, Claire
AU  - Gargiulo, Piera
AU  - Berger, Regina
AU  - Ochi, Hiroyuki
AU  - Vergote, Ignace
AU  - Colombo, Nicoletta
AU  - Mirza, Mansoor R
AU  - Tazi, Youssef
AU  - Canzler, Ulrich
AU  - Zamagni, Claudio
AU  - Guerra-Alia, Eva M
AU  - Levaché, Charles B
AU  - Marmé, Frederik
AU  - Bazan, Fernando
AU  - de Gregorio, Nikolaus
AU  - Dohollou, Nadine
AU  - Fasching, Peter A
AU  - Scambia, Giovanni
AU  - Rubio-Pérez, María J
AU  - Milenkova, Tsveta
AU  - Costan, Cristina
AU  - Pautier, Patricia
AU  - Ray-Coquard, Isabelle
AU  - PAOLA1/ENGOT-ov25 investigators
PY  - 2022
DO  - 10.1016/j.ejca.2022.07.022
UR  - http://hdl.handle.net/10668/22178
T2  - European journal of cancer (Oxford, England : 1990)
AB  - PAOLA-1/ENGOT-ov25 (NCT02477644) demonstrated a significant progression-free survival (PFS) benefit with maintenance olaparib plus bevacizumab versus placebo plus bevacizumab in newly diagnosed, advanced ovarian cancer. We report the prespecified main...
LA  - en
KW  - Antiangiogenic agent
KW  - Bevacizumab
KW  - Olaparib
KW  - Ovarian cancer
KW  - PARP inhibitor
KW  - Second progression-free survival
KW  - Antineoplastic Agents
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Bevacizumab
KW  - Carcinoma, Ovarian Epithelial
KW  - Double-Blind Method
KW  - Female
KW  - Humans
KW  - Ovarian Neoplasms
KW  - Phthalazines
KW  - Piperazines
KW  - Poly(ADP-ribose) Polymerase Inhibitors
KW  - Progression-Free Survival
TI  - Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial.
TY  - research article
VL  - 174
ER  -